Current Gastroenterology Reports

, Volume 6, Issue 1, pp 10–16 | Cite as

Pruritus in chronic liver disease: Mechanisms and treatment

  • Nora V. Bergasa


Pruritus is a complication of liver disease. It can have a marked negative impact on quality of life; when intractable, it is an indication for liver transplantation. The cause of this type of pruritus is unknown. There is, however, evidence to suggest that the pruritus associated with liver disease is mediated, at least in part, by endogenous opioids. A central mechanism has been proposed. Therapeutic interventions have concentrated on the removal of presumed and unknown pruritogens from the circulation, hepatic enzyme induction, and, over the past decade, opiate antagonists, the first specific treatment for the pruritus of cholestasis. Other pharmacologic interventions that change neurotransmission have recently been reported to decrease the pruritus in patients with liver disease, as has a newly developed system that applies albumin-based dialysis. These interventions are promising, but they must be tested in properly controlled behavioral trials.


Naloxone Ondansetron Primary Biliary Cirrhosis Cholestasis Naltrexone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Greaves MW, Wall PD: Pathophysiology of itching. Lancet 1996, 348:938–940.PubMedCrossRefGoogle Scholar
  2. 2.
    LaMotte RH: Subpopulations of ‘nocifensor neurons’ contributing to pain and allodynia, itch and alloknesis. Am Pain Soc J 1992, 1:115–126.Google Scholar
  3. 3.
    Schmelz M, Schmidt R, Bickel A, et al.: Specific C-receptors for itch in human skin. J Neurosci 1997, 17:8003–8008. A landmark study identifying specific "itch" receptors.PubMedGoogle Scholar
  4. 4.
    Andrew D, Craig AD: Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001, 4:72–77.PubMedCrossRefGoogle Scholar
  5. 5.
    Massey E: Unilateral neurogenic pruritus following stroke. Stroke 1984, 15:901–903.PubMedGoogle Scholar
  6. 6.
    Shapiro P, Braun C: Unilateral pruritus after a stroke. Arch Dermatol 1987, 123:1521–1530.CrossRefGoogle Scholar
  7. 7.
    Osterman P: Paroxysmal itching in multiple sclerosis. Br J Dermatol 1976, 95:555–558.PubMedCrossRefGoogle Scholar
  8. 8.
    Ballantyne JC, Loach AB, Carr DB: Itching after epidural and spinal opiates. Pain 1988, 33:149–160.PubMedCrossRefGoogle Scholar
  9. 9.
    Ballantyne JC, Loach AB, Carr DB: The incidence of pruritus after epidural morphine. Anaesthesia 1989, 44:863.PubMedCrossRefGoogle Scholar
  10. 10.
    Dailey PA, Brookshire GL, Shnider SM, et al.: The effects of naloxone associated with the intrathecal use of morphine in labor. Anesth Analg 1985, 64:658–666.PubMedCrossRefGoogle Scholar
  11. 11.
    Oliveras J, Maixner W, Dubner R, et al.: The medullary dorsal horn: a target for the expression of opiate effects on the perceived intensity of noxious heat. J Neurosci 1986, 6:3086–3093.PubMedGoogle Scholar
  12. 12.
    Thomas DA, Williams GM, Iwata K, et al.: Effects of central administration of opioids on facial scratching in monkeys. Brain Res 1992, 585:315–317.PubMedCrossRefGoogle Scholar
  13. 13.
    Thomas DA, Hammond DL: Microinjection of morphine into the rat medullary dorsal horn produces a dose-dependent increase in facial scratching. Brain Res 1995, 695:267–270.PubMedCrossRefGoogle Scholar
  14. 14.
    Jinks SL, Carstens E: Superficial dorsal horn neurons identified by intracutaneous histamine: chemonociceptive responses and modulation by morphine. J Neurophysiol 2000, 84:616–627.PubMedGoogle Scholar
  15. 15.
    Aoki T: Pleasure of ’scratch’ is a complex sensation of itch and pain. Presented at the Second International Workshop for the Study of Itch. Toyama, Japan, October 24, 2003.Google Scholar
  16. 16.
    Reichen J, Simon F: Cholestasis. In The Liver: Biology and Pathobiology,edn 2. Edited by Arias IMJW, Popper H, Schachter D,Schafrits DA. New York: Raven Press, 1988:1105–1124.Google Scholar
  17. 17.
    Bergasa NV, Jones EA: The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995, 108:1582–1588.PubMedCrossRefGoogle Scholar
  18. 18.
    Thornton JR, Losowsky MS: Opioid peptides and primary biliary cirrhosis. BMJ 1988, 297:1501–1504. A landmark paper. In this publication, evidence suggesting that central opioidergic neurotransmission is increased in cholestatis was presented. The authors also reported that pruritus, as assessed subjectively, decreased in association with the opiate antagonist nalmefene.PubMedGoogle Scholar
  19. 19.
    Bergasa NV, Alling DW, Vergalla J, Jones EA: Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994, 20:85–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Bergasa NV, Rothman RB, Vergalla J, et al.: Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J Hepatol 1992, 15:220–224.PubMedCrossRefGoogle Scholar
  21. 21.
    Bergasa NV, Sabol SL, Young et al.: Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995, 268:G346-G354.PubMedGoogle Scholar
  22. 22.
    Bergasa N: Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002, 22:107–113.PubMedCrossRefGoogle Scholar
  23. 23.
    Dagenais C, Ducharme J, Pollack GM: Uptake and efflux of the peptidic delta-opioid receptor agonist. Neurosci Lett 2001, 301:155–158.PubMedCrossRefGoogle Scholar
  24. 24.
    Banks WA, Kastin AJ: Peptide transport systems for opiates across the blood-brain barrier. Am J Physiol 1990, 259:E1-E10.PubMedGoogle Scholar
  25. 25.
    Sherlock S, Dooley J: Cholestasis. In Diseases of the Liver and Biliary System, edn 9. Edited by Sherlock S. London: Blackwell;1991:214–235.Google Scholar
  26. 26.
    Sherlock S, Dooley J. Primary biliary cirrhosis. In Diseases of the Liver and Biliary System, edn 9. Edited by Sherlock S. London:Blackwell, 1991:236–248.Google Scholar
  27. 27.
    Talwalkar JA, Souto E, Beigley CS, et al.: Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol2003, in press.Google Scholar
  28. 28.
    Poupon R, Chazouilleres O, Balkau B, Poupon RE: Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group. J Hepatol 1999, 30:408–412.PubMedCrossRefGoogle Scholar
  29. 29.
    Woolf GM, Reynold TB: Failure of rifampicin to relieve pruritus in chronic liver disease. J Clin Gastroenterol 1990, 12:174–177.PubMedGoogle Scholar
  30. 30.
    Fisher DA, Wright TL: Pruritus as a symptom of hepatitis C. J Acad Dermatol 1994, 30:629–632.Google Scholar
  31. 31.
    Lebovics E, Seif F, Kim D, et al.: Pruritus in chronic hepatitis C. Dig Dis Sci 1997, 42:1094–1099.PubMedCrossRefGoogle Scholar
  32. 32.
    Chia SC, Bergasa NV, Kleiner DE, et al.: Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci 1998, 43:2177–2183.PubMedCrossRefGoogle Scholar
  33. 33.
    Doria C, Mandala L, Smith J, et al.: Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl 2003, 9:437–443. A well-balanced report on a preliminary experience in the use of MARS for treatment of pruritus in patients with liver disease.PubMedCrossRefGoogle Scholar
  34. 34.
    Savin J, Paterson W, Oswald I: Scratching during sleep. Lancet 1973, ii:296–297.CrossRefGoogle Scholar
  35. 35.
    Savin J, Paterson W, Oswald I, Adam K: Further studies of scratching during sleep. Br J Dermatol 1975, 93:297–302.PubMedCrossRefGoogle Scholar
  36. 36.
    Talbot TL, Schmitt JM, Bergasa NV, et al.: Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrum Technol 1991, 25:400–403. A technical paper on the development of a scratching activity monitoring system that allows for quantitation of scratching behavior independently from gross body movements.PubMedGoogle Scholar
  37. 37.
    Molenaar HA, Oosting J, Jones EA: Improved device for measuring scratching activity in patients with pruritus. Med Biol Eng Comput 1998, 36:220–224.PubMedCrossRefGoogle Scholar
  38. 38.
    Bergasa NV, Talbot TL, Alling DW, et al.: A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992, 102:544–549.PubMedGoogle Scholar
  39. 39.
    Bergasa NV, Talbot TL, Schmitt JP, et al.: Open label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998, 27:679–684.PubMedCrossRefGoogle Scholar
  40. 40.
    Bergasa NV, Alling DW, Talbot TL, et al.: Naloxone ameliorates the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Ann Intern Med 1995, 123:161–167. The first double-blind, randomized, placebo-controlled study that applied quantitative methodology and demonstrated that the behavior resulting from pruritus—scratching—was significantly decreased by opiate antagonists.PubMedGoogle Scholar
  41. 41.
    O’Donohue JW, Haigh C, Williams R: Ondansetron in the treatment of the pruritus of cholestasis: a randomised controlled trial [abstract]. Gastroenterology 1997, 112:A1349.Google Scholar
  42. 42.
    Bergasa NV, Alling DW, Talbot TL, et al.: Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999, 41:431–434.PubMedCrossRefGoogle Scholar
  43. 43.
    Datta DV, Sherlock S: Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966, 50:323–332. One of the first clinical trials of cholestyramine for pruritus in cholestasis.PubMedGoogle Scholar
  44. 44.
    Berg C: Use of colesevelam hydrochloride (Welchol) as a novel therapeutic agent for the management of refractory pruritus in chronic liver disease. Hepatology 2001, 34:541.Google Scholar
  45. 45.
    Cohen LB, Ambinder EP, Wolke AM, et al.: Role of plasmapheresis in primary biliary cirrhosis. Gut 1985, 26:291–294.PubMedGoogle Scholar
  46. 46.
    Ambinder EP, Cohen LB, Wolke AM, et al.: The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis. J Clin Apheresis 1985, 2:219–223.PubMedCrossRefGoogle Scholar
  47. 47.
    Stange J, Mitzner SR, Risler T, et al.: Molecular adsorbent recycling system (MARS): clinical results of a new membranebased blood purification system for bioartificial liver support. Artif Organs 1999, 23:319–330.PubMedCrossRefGoogle Scholar
  48. 48.
    Stange J, Hassanein TI, Mehta R, et al.: The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002, 26:103–110.PubMedCrossRefGoogle Scholar
  49. 49.
    Sturm E, Franssen CF, Gouw A, et al.: Extracorporal albumin dialysis (MARS) improves cholestasis and normalizes low apo A-I levels in a patient with benign recurrent intrahepatic cholestasis (BRIC). Liver 2002, 22(Suppl 2):72–75.PubMedGoogle Scholar
  50. 50.
    Emerick KM, Whitington PF: Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 2002, 35:1501–1506.PubMedCrossRefGoogle Scholar
  51. 51.
    Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, et al.:Ileal exclusion for Byler’s disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 1998, 33:220–224.PubMedCrossRefGoogle Scholar
  52. 52.
    Bloomer JR, Boyer JL: Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975, 82:310–317.PubMedGoogle Scholar
  53. 53.
    Ghent CN, Bloomer JR, Hsia YE: Efficacy and safety of longterm phenobarbital therapy of familial cholestasis. J Pediatr 1978, 93:127–132.PubMedCrossRefGoogle Scholar
  54. 54.
    Ghent CN, Carruthers SG: Treatment of pruritus in primary biliary cirrhosis with rifampin: results of a double-blind, crossover, randomized trial. Gastroenterology 1988, 94:488–493. The first controlled trial on the use of rifampicin to treat pruritus in cholestasis.PubMedGoogle Scholar
  55. 55.
    Bachs L, Par’es A, Elena M, et al.: Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992, 102:2077–2080.PubMedGoogle Scholar
  56. 56.
    Ghent CN: Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. Am J Gastroenterol 1987, 82:117–118.PubMedGoogle Scholar
  57. 57.
    Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002, 50:436–439. Informative paper on the potential risk of rifampicin therapy.PubMedCrossRefGoogle Scholar
  58. 58.
    Mullally BA, Hansen WF: Intrahepatic cholestasis of pregnancy: review of the literature. Obstet Gynecol Surv 2002, 57:47–52. Report of an analysis of published papers on the use of ursodeoxycholic acid in cholestasis of pregnancy.PubMedCrossRefGoogle Scholar
  59. 59.
    Carson KL, Tran TT, Cotton P, et al.: Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996, 91:1022–1023.PubMedGoogle Scholar
  60. 60.
    Wolfhagen FHJ, Sternieri E, Hop WCJ, et al.: Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebocontrolled study. Gastroenterology 1997, 113:1264–1269. First controlled trial of naltrexone for the pruritus of cholestasis.PubMedCrossRefGoogle Scholar
  61. 61.
    Terg R, Coronel E, Sorda J, et al.: Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002, 3:717–722.CrossRefGoogle Scholar
  62. 62.
    Mitchell JE: Naltrexone and hepatotoxicity. Lancet 1986, i:1215.CrossRefGoogle Scholar
  63. 63.
    Krystal JH, Cramer JA, Krol et al.: Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001, 345:1734–1739.PubMedCrossRefGoogle Scholar
  64. 64.
    Lloyd-Thomas HGL, Sherlock S: Testosterone therapy for the pruritus of obstructive jaundice. BMJ 1952, 2:1289–1291.PubMedCrossRefGoogle Scholar
  65. 65.
    Richardson BP: Serotonin and nociception. Ann N Y Acad Sci 1990, 600:511–520.PubMedCrossRefGoogle Scholar
  66. 66.
    Schwör H, Ramadori G: Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Investig 1993, 71:659–662.Google Scholar
  67. 67.
    Raderer M, Muller C, Scheithauer W: Ondansetron for pruritus due to cholestasis. N Engl J Med 1994, 21:1540.CrossRefGoogle Scholar
  68. 68.
    Schworer H, Hartmann H, Ramadori G: Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995, 61:33–37.PubMedCrossRefGoogle Scholar
  69. 69.
    Muller C, Pongratz S, Pidlich J, et al.: Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998, 10:865–870.PubMedGoogle Scholar
  70. 70.
    Neff GW, O’Brien CB, Reddy KR, et al.: Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002, 97:2117–2119.PubMedCrossRefGoogle Scholar
  71. 71.
    Neff GW, O’Brien CB, Regev A, et al.: The remedy for intractable cholestatic related pruritus (ICRP): delta-9-tetrahydrocannabinol (Marinol) [abstract]. Hepatology 1999, 30:328A.Google Scholar
  72. 72.
    Fuentes JA, Ruiz-Gayo M, Manzanares J, et al.: Cannabinoids as potential new analgesics. Life Sci 1999, 65:675–685.PubMedCrossRefGoogle Scholar
  73. 73.
    Gingold AR, Bergasa NV: The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sci 2003, 73:2741–2747.PubMedCrossRefGoogle Scholar
  74. 74.
    Gabapentin. In Physicians’ Desk Reference. Montvale: Medical Economics Company; 2000.Google Scholar
  75. 75.
    Backonja M, Glanzman RL: Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003, 25:81–104.PubMedCrossRefGoogle Scholar
  76. 76.
    Bueller HA, Bernhard JD, Dubroff LM: Gabapentin treatment for brachioradial pruritus. J Eur Acad Dermatol Venereol 1999, 13:227–228.PubMedCrossRefGoogle Scholar
  77. 77.
    Bernhard JD: Itching as a manifestation of noncutaneous disease. Hosp Pract (Off Ed) 1987, 22(1A):81–86.Google Scholar
  78. 78.
    Browning JD, Combes B, Mayo M: Sertraline: evidence for a role in the treatment of cholestatic pruritus T1105. Gastroenterology 2002, 123(1 Suppl):66.Google Scholar
  79. 79.
    Jones EA, Dekker LR: Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis [abstract]. Gastroenterology 2002, 123(Suppl 1):66. Helpful recommendations on how to use opiate antagonists.Google Scholar
  80. 80.
    Jones EA, Neuberger J, Bergasa NV: Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002, 95:547–552.PubMedCrossRefGoogle Scholar
  81. 81.
    Moore RY: Organization of the mammalian circadian system.In Circadian Clocks and Their Readjustments. Edited by Chadwick DJ, Ackrill K. London: John Wiley & Sons, 1993:88–106.Google Scholar
  82. 82.
    Bergasa NV, Link MJ, Keogh M, et al.: Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001, 96:1563–1570.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Nora V. Bergasa
    • 1
  1. 1.Division of Digestive and Liver DiseasesColumbia University College of Physicians and SurgeonsNew YorkUSA

Personalised recommendations